revenue

A quick summary of the financials from the last 5 quarterly reports,

	Column 1	Column 2	Column 3	Column 4	Column 5	Column 6
0		Dec-14	Mar-15	Jun-15	Sep-15	Dec-15
1	Receipts from product sales and related debtors ($1000's)	21	131	250	24	100
2
3	Payments for (a) exploration & evaluation	-54	-1	-85	-6	-21
4	(b) development
5	(c) production
6	(d) administration	-54	-99	-219	-247	-327
7	(e) other	-998	-715	-776	-813	-1,083
8
9		-261	-684	-863	-1041	-1331

Not sure what the revenue for the reported commercial orders would have been, or if included in the upcoming report, but, with the gradual increase in expenses (both administration and other costs both increased more than 30% in the last quarter),   I get the feeling that rising costs may be a prominent feature in the upcoming report.

Am a believer and plan to hold for quite a while, but, if achieving a cash flow positive status is a mile stone, we may not be meeting it for a while, and am prepared for an 'appropriate' reaction from the market next week.

I am a holder in another 'disruptive' technology company (from Australia - Aussie Aussie Aussie Oi Oi Oi) in a very similar position - new game changing product, slowly demonstrating comparable features (and now demonstrating superior performance with formal clinical trials for additional uses being conducted) to the existing products - huge impact on peoples lives and health - on a global nature, had a 10 bag run up in SP, however fell back to less than double the original SP  and now , the SP languishes......................as the cash flow is very negative - company spending $2 for every $1 they make and a number of capitol raising ventures in these early days.

We holders are all dreaming of the blue sky SP that could be ( and likely will be) achieved.....but with every quarterly that shows revenue being outstripped by costs, market sentiment  is what it is, and reflected in the SP.

Not being pessimistic and believe in the 2-6 year plan, but being prepared for a bit of a rocky ride.

6 sleeps